title: Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials.
abstract: A retrospective person-time analysis of the randomized and non-randomized extension phases of four phase III trials was performed to assess the incidence of adverse cardiovascular events in 2680 HIV-infected patients receiving indinavir or nucleoside reverse transcriptase inhibitor therapy, or both. The observed rate of cardiovascular events was not increased in patients receiving indinavir-based regimens compared with therapy without a protease inhibitor. Extrapolation of these findings is limited by the brief length of therapy and the small number of cases.
authors.affiliation: Merck Research Laboratories, West Point, PA, USA.
authors.forename: P M
authors.initials: PM
authors.lastname: Coplan
authors.forename: A A
authors.initials: AA
authors.lastname: Nikas
authors.forename: R Y
authors.initials: RY
authors.lastname: Leavitt
authors.forename: L
authors.initials: L
authors.lastname: Doll
authors.forename: M L
authors.initials: ML
authors.lastname: Nessly
authors.forename: M J
authors.initials: MJ
authors.lastname: DiNubile
authors.forename: H A
authors.initials: HA
authors.lastname: Guess
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000209:etiology*; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019469:Indinavir / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019469:Indinavir